skip to primary navigationskip to content

Cambridge Institute for Medical Research

Department A-Z

Our strategy

We aim to create an inspiring environment in which outstanding scientists can excel. By providing state-of-the-art core facilities and support for our researchers, we foster new collaborations that spark discoveries about fundamental cellular processes and their relevance in disease.

Read more

Research advances

In Nature Communications, the Lehner lab compare genome-wide CRISPR/Cas9-mediated forward genetic screens with gene-trap mutagenesis screens in haploid human cells, identifying new factors that control mammalian ER-associated degradation of MHC class I molecules.

Read more

Research advances

In Traffic, the Deane lab have revealed a new cell biological framework for pathogenesis of the fatal neurodegenerative disorder Krabbe Disease, by characterizing a series of disease mutations in the lysosomal enzyme galactocerebrosidase (GALC).

Read more

GSK discovery partnership

A new collaboration between the Lehner lab and GSK, part of their Discovery Partnerships with Academia (DPAc) initiative, will aim to develop and commercialise new treatments for HIV that target latent virus.

Read more

Thudichum Medal award

Congratulations to David Rubinsztein, whose award from the Biochemical Society recognizes his outstanding contributions to the field of neuroscience.

Read more

A unique partnership between basic and clinical research, aiming to understand the cellular basis of disease

New publications


Lehner lab (Traffic 2016)

Trafficking control of tetherin.


Rubinsztein lab (Nature Comm. 2016)

Autophagy-lysosome dysfunction in Parkinson's disease.


Lehner lab (Nature Comm. 2016)

Forward-genetic screens of mammalian ER-associated degradation.


Deane lab (Traffic 2016)

Uncovering Krabbe Disease pathogenesis.


Smith lab (PLoS Genet. 2016)

eQTL mapping of immune disease.


Maxwell lab (Sci. Rep. 2016)

Targeting hypoxic cancer cells.


Ron lab (eLife 2016)

AMPylation of BiP ER chaperone.